Retatrutide, also known as LY3437943, is an investigational peptide designed to activate the GLP-1, GIP and glucagon receptors. The three receptor targets are features of the molecule’s design.
GLP-1, GIP and glucagon
A receptor description gives researchers a way to test hypotheses about metabolism. Clinical trials then measure outcomes in people and record harms. Neither the count of targets nor the name of a receptor quantifies the effect on body weight.
How to interpret the evidence
Look for a source that distinguishes laboratory receptor experiments from randomized clinical outcomes. Phase 2 obesity data supply an early human comparison against placebo.
Start with the intervention name and receptor targets, then follow the links to the original trial if you want to check what was measured in people.